Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy

21 May 2024

Abstract excerpt

BACKGROUND AND PURPOSE: Cystic fibrosis (CF) patients are living longer and healthier due to improved treatments, e.g. cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI), with treatment possibly occurring in pregnancy. The risk of ETI to foetuses remain unknown. Thus the effect of maternally administered ETI on foetal genetic and structural...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Cystic Fibrosis Research Advances
Share to Neonatal Respiratory Health Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38770951
DOI: 10.1111/bph.16417

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancyPMID 38770951Read ↗

Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.Semantic proximity Read ↗

"Shifting sands in cystic fibrosis": impacts of CFTR modulators on reproductive health in people with cystic fibrosis and challenges related to in utero exposure.Semantic proximity Read ↗

Use of CFTR modulators in special populations, part 1: Pregnancy and lactation.Semantic proximity Read ↗

CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: Insights from an unsuccessful caseSemantic proximity Read ↗

Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.Semantic proximity Read ↗

Gene and Stem Cell Therapies for Fetal CareSemantic proximity Read ↗

Protective and sex‐specific effects of moderate dose folic acid supplementation on the placenta following assisted reproduction in miceSemantic proximity Read ↗

Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.Semantic proximity Read ↗

Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor (ETI) suggest benefits beyond improved CFTR channel functionSemantic proximity Read ↗

A multidisciplinary model for prenatal care for patients with cystic fibrosis in the era of highly effective modulator therapy.Semantic proximity Read ↗

Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosisSemantic proximity Read ↗

Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor suggest benefits beyond improved CFTR channel functionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.